세계의 의약품 CDMO 시장 규모 조사 및 예측 : 제품별, 워크플로우별, 용도별, 지역별 분석(2023-2030년)

Global Pharmaceutical CDMO Market is valued approximately at USD 136.94 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.1% over the forecast period 2023-2030. Pharmaceutical CDMO (Contract Development and Manufacturing Organization) is a type of company that provides outsourced services for the pharmaceutical industry, including drug development, manufacturing, and packaging. CDMOs work on behalf of pharmaceutical companies that do not have the internal resources, expertise, or facilities to undertake certain aspects of drug development or manufacturing.

Numerous causes, such as the rising demand for biopharmaceuticals, improvements in manufacturing technology, and the tendency to outsource medication development and manufacture, are responsible for the expansion. The pharmaceutical industry's contract development and manufacturing organization (CDMO) market is a crucial one, and its expansion is anticipated to benefit the entire healthcare sector.

The pharmaceutical CDMO market is expected to grow in the future years as a result of the industry's significant R&D expenditures and the expanding need for biopharmaceuticals. The market for medicines is likely to expand as the ageing population creates new opportunities for drug development. Since they provide pharmaceutical businesses with cost-effective solutions and a shorter time to market through the outsourcing of drug development and production, CDMOs are an essential component of the pharmaceutical industry. In addition, the rise of the biopharma industry, with China emerging as a prominent player, is anticipated to accelerate. Pharmaceutical businesses continually invest in R&D, which is fueling improvements in biopharmaceuticals and the development of fresh therapies and cures. It is anticipated that this pattern would continue, with the top 15 businesses spending a record amount on R&D in 2020. Global pharmaceutical R&D investment is anticipated to increase due to the rising prevalence of chronic diseases and the creation of biosimilars, thus boosting the market's expansion. In general, the pharmaceutical CDMO future is bright, with several expansion potential opening in the pharmaceutical sector. Additionally, the market is expanding due to the rising incidence of cancer worldwide, which will account for 10 million deaths worldwide in 2021 and be the leading cause of death. It is anticipated that there would be an increase in the demand for innovative cancer therapies, creating opportunities for pharmaceutical and CDMO businesses. In 2020, it is anticipated that the pipeline for oncology medicines in the pharmaceutical sector would make up about 30% of it. With more than 12.5 million new instances of cancer diagnosed each year, the oncology sector is still difficult, time-consuming, and evolving despite the advances in detection and treatment. However, the high cost of Pharmaceutical CDMO stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Pharmaceutical CDMO Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. The market is divided into different geographic segments, with Asia Pacific expected to have the quickest CAGR growth throughout the projected period and have the greatest market share in 2022. The APAC region's market expansion can be attributable to lower manufacturing costs than those in North America and Europe, which makes it a desirable outsourcing hub for the creation of pharmaceuticals. The region's market is expanding due to the presence of university-affiliated pharmaceutical research hubs and significant funding. Due to favorable legislation and much lower production costs in North America and Europe, India and China are leading the market for contract development and manufacturing organizations.

Major market players included in this report are:

• Bushu Pharmaceuticals Ltd.
• Nipro Corporation
• Thermo Fisher Scientific Inc.
• Samsung Biologics
• Laboratory Corporation of America Holdings
• Siegfried Holding Ag
• Catalent, Inc
• Lonza Group AG
• Recipharm Ab
• Piramal Pharma Solutions

Recent Developments in the Market:

• In 2020, WuXi AppTec, a Chinese-based Pharmaceutical CDMO, announced the launch of a new digital technology platform to enable end-to-end supply chain management for the pharmaceutical industry.
• Some Pharmaceutical CDMOs are adopting sustainability initiatives to reduce their environmental impact. In 2021, Lonza announced its commitment to achieve net-zero greenhouse gas emissions by 2050 and to reduce its carbon footprint by 50% by 2030.

Global Pharmaceutical CDMO Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Product, Workflow, Application, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

• API
• Drug

By Workflow:

• Clinical
• Commercial

By Application:

• Oncology
• Hormonal
• Glaucoma
• Cardiovascular Disease
• Diabetes
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Pharmaceutical CDMO Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Pharmaceutical CDMO Market, by Product, 2020-2030 (USD Billion)
  • 1.2.3. Pharmaceutical CDMO Market, by Workflow, 2020-2030 (USD Billion)
  • 1.2.4. Pharmaceutical CDMO Market, by Application, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Pharmaceutical CDMO Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Pharmaceutical CDMO Market Dynamics

• 3.1. Pharmaceutical CDMO Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing demand for biopharmaceuticals
    • 3.1.1.2. Increasing Cases of Cancer across the Globe
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Pharmaceutical CDMO
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Technological advancements in manufacturing

Chapter 4. Global Pharmaceutical CDMO Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Pharmaceutical CDMO Market, by Product

• 5.1. Market Snapshot
• 5.2. Global Pharmaceutical CDMO Market by Product, Performance - Potential Analysis
• 5.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 5.4. Pharmaceutical CDMO Market, Sub Segment Analysis
  • 5.4.1. API
  • 5.4.2. Drug

Chapter 6. Global Pharmaceutical CDMO Market, by Workflow

• 6.1. Market Snapshot
• 6.2. Global Pharmaceutical CDMO Market by Workflow, Performance - Potential Analysis
• 6.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Workflow 2020-2030 (USD Billion)
• 6.4. Pharmaceutical CDMO Market, Sub Segment Analysis
  • 6.4.1. Clinical
  • 6.4.2. Commercial

Chapter 7. Global Pharmaceutical CDMO Market, by Application

• 7.1. Market Snapshot
• 7.2. Global Pharmaceutical CDMO Market by Application, Performance - Potential Analysis
• 7.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 7.4. Pharmaceutical CDMO Market, Sub Segment Analysis
  • 7.4.1. Oncology
  • 7.4.2. Hormonal
  • 7.4.3. Glaucoma
  • 7.4.4. Cardiovascular Disease
  • 7.4.5. Diabetes
  • 7.4.6. Others

Chapter 8. Global Pharmaceutical CDMO Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Pharmaceutical CDMO Market, Regional Market Snapshot
• 8.4. North America Pharmaceutical CDMO Market
  • 8.4.1. U.S. Pharmaceutical CDMO Market
    • 8.4.1.1. Product breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Workflow breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Application breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Pharmaceutical CDMO Market
• 8.5. Europe Pharmaceutical CDMO Market Snapshot
  • 8.5.1. U.K. Pharmaceutical CDMO Market
  • 8.5.2. Germany Pharmaceutical CDMO Market
  • 8.5.3. France Pharmaceutical CDMO Market
  • 8.5.4. Spain Pharmaceutical CDMO Market
  • 8.5.5. Italy Pharmaceutical CDMO Market
  • 8.5.6. Rest of Europe Pharmaceutical CDMO Market
• 8.6. Asia-Pacific Pharmaceutical CDMO Market Snapshot
  • 8.6.1. China Pharmaceutical CDMO Market
  • 8.6.2. India Pharmaceutical CDMO Market
  • 8.6.3. Japan Pharmaceutical CDMO Market
  • 8.6.4. Australia Pharmaceutical CDMO Market
  • 8.6.5. South Korea Pharmaceutical CDMO Market
  • 8.6.6. Rest of Asia Pacific Pharmaceutical CDMO Market
• 8.7. Latin America Pharmaceutical CDMO Market Snapshot
  • 8.7.1. Brazil Pharmaceutical CDMO Market
  • 8.7.2. Mexico Pharmaceutical CDMO Market
• 8.8. Middle East & Africa Pharmaceutical CDMO Market
  • 8.8.1. Saudi Arabia Pharmaceutical CDMO Market
  • 8.8.2. South Africa Pharmaceutical CDMO Market
  • 8.8.3. Rest of Middle East & Africa Pharmaceutical CDMO Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Bushu Pharmaceuticals Ltd.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Nipro Corporation
  • 9.3.3. Thermo Fisher Scientific Inc.
  • 9.3.4. Samsung Biologics
  • 9.3.5. Laboratory Corporation of America Holdings
  • 9.3.6. Siegfried Holding Ag
  • 9.3.7. Catalent, Inc
  • 9.3.8. Lonza Group AG
  • 9.3.9. Recipharm Ab
  • 9.3.10. Piramal Pharma Solutions

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption